Personalized support programs with innovative digital tools to manage and monitor patients suffering from epilepsy: EpiOnApp case study

Luca Buscioni, Giancarlo Di Gennaro, Claudia Passamonti
{"title":"Personalized support programs with innovative digital tools to manage and monitor patients suffering from epilepsy: EpiOnApp case study","authors":"Luca Buscioni, Giancarlo Di Gennaro, Claudia Passamonti","doi":"10.33393/grhta.2023.2888","DOIUrl":null,"url":null,"abstract":"Epilepsy is one of the most common serious chronic neurological diseases affecting around 50 million people globally and 500,000 patients in Italy. It causes uncontrollable, unprovoked, and unpredictable seizures that reduce the quality of life of those afflicted. It is widely recognized that the most important strategy for controlling seizures and enhance well-being includes receiving and adhering to anti-seizure medications as well as making appropriate lifestyle adjustments. However it is estimated that 30–60% of patients do not adhere to their antiepileptic medication regimens. EpiOnApp is a digital Patients Support Program (PSP) designed to empower patients with epilepsy who are taking Cenobamate for their chronic condition to take control of their health care pathway, from inception throughout the duration of the treatment, and to have a meaningful dialogue with their neurologist by sharing health records and emotional states. Moreover, as patients may have limited mobility, they can order their therapy and have it home delivered in a very easy way, and they can benefit from continuous human support through the figure of a dedicated Care Manager. The advantage for the neurologist is that the platform stores seizure data, facilitating the drug titration and better assessing at the time of the follow-up visit. The efficacy of the program is currently being evaluated. So far, the level of satisfaction expressed by patients and neurologists shows that a well-designed and tailored PSP can address the challenge of improving long-term adherence, helping people with epilepsy through the on-boarding and initial treatment period, reducing discontinuation, and ultimately, delivering a better health outcome.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global and Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2023.2888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Epilepsy is one of the most common serious chronic neurological diseases affecting around 50 million people globally and 500,000 patients in Italy. It causes uncontrollable, unprovoked, and unpredictable seizures that reduce the quality of life of those afflicted. It is widely recognized that the most important strategy for controlling seizures and enhance well-being includes receiving and adhering to anti-seizure medications as well as making appropriate lifestyle adjustments. However it is estimated that 30–60% of patients do not adhere to their antiepileptic medication regimens. EpiOnApp is a digital Patients Support Program (PSP) designed to empower patients with epilepsy who are taking Cenobamate for their chronic condition to take control of their health care pathway, from inception throughout the duration of the treatment, and to have a meaningful dialogue with their neurologist by sharing health records and emotional states. Moreover, as patients may have limited mobility, they can order their therapy and have it home delivered in a very easy way, and they can benefit from continuous human support through the figure of a dedicated Care Manager. The advantage for the neurologist is that the platform stores seizure data, facilitating the drug titration and better assessing at the time of the follow-up visit. The efficacy of the program is currently being evaluated. So far, the level of satisfaction expressed by patients and neurologists shows that a well-designed and tailored PSP can address the challenge of improving long-term adherence, helping people with epilepsy through the on-boarding and initial treatment period, reducing discontinuation, and ultimately, delivering a better health outcome.
利用创新数字工具管理和监测癫痫患者的个性化支持计划:EpiOnApp 案例研究
癫痫是最常见的严重慢性神经系统疾病之一,全球约有 5000 万患者,意大利有 50 万患者。它导致无法控制、无诱因和不可预测的癫痫发作,降低了患者的生活质量。 人们普遍认为,控制癫痫发作和提高生活质量的最重要策略包括接受和坚持服用抗癫痫药物,以及适当调整生活方式。然而,据估计有 30-60% 的患者没有坚持服用抗癫痫药物。EpiOnApp是一个数字化的患者支持计划(PSP),旨在让服用塞诺巴马特治疗慢性病的癫痫患者从开始治疗到整个治疗期间都能掌控自己的医疗保健途径,并通过分享健康记录和情绪状态与神经科医生进行有意义的对话。此外,由于患者可能行动不便,他们可以非常方便地订购治疗方案并送货上门,还可以通过专门的护理经理获得持续的人力支持。对于神经科医生来说,该平台的优势在于可以存储癫痫发作数据,方便药物滴定,并在随访时进行更好的评估。目前正在对该计划的效果进行评估。到目前为止,患者和神经科医生的满意度表明,精心设计和量身定制的 PSP 可以应对改善长期依从性的挑战,帮助癫痫患者度过入院和初始治疗期,减少停药,最终实现更好的健康结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信